ClinicalTrials.gg

Program

TQC2938

A development code. Also written as “TQC2938 injection” and “TQC2938 Injection”.

In Sino Biopharmaceutical's pipeline, ST2 (IL-33R) 单抗. Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Asthma, led by Sino Biopharmaceutical.

Furthest: phase 2, since Jan 17, 20253 company-led studies, 2 open or runningNext primary completion: Mar 17, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical32 open or runningphase 2since Jan 17, 2025Jun 3, 2024Mar 17, 2027phase 2 · NCT06789289
  • Named in Sino Biopharmaceutical’s own pipeline as TQC2938, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 3, 2024First study: phase 1 study in AsthmaFirst studyNCT06449859 · 84 enrolled · China
  2. Jan 17, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06789289 · 256 enrolled · China
  3. Jun 8, 2025Phase 2 study in Rhinitis, Allergic, SeasonalNCT07052097 · 136 enrolled · China

Ahead

  1. Mar 17, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06789289

TargetBeta

“ST2 (IL-33R) 单抗”the company's pipeline, read by Claude · source

Other programs on IL33R

ProgramCompanyFurthest phaseStudies
astegolimabHoffmann-La Rochephase 39

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07052097Rhinitis, Allergic, Seasonal · China2CompletedSep 12, 2025136
NCT06789289Pulmonary Disease, Chronic Obstructive · China2Active, not recruitingMar 17, 2027256
NCT06449859Asthma · China1Active, not recruitingNov 202484

How it is read

Names in the registry

  • “TQC2938 injection”, 2 entries
  • “TQC2938 Injection”, 1 entry

Codes read as this program: TQC2938.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.